T cell engagers

Antibodies
#License agreement #Roche #T cell engagers #Therapeutic Antibodies #Zymeworks

Roche licenses Zymeworks’ trispecific T cell engager targeting DLL3

Zymeworks has entered into a global license and collaboration agreement with Roche for the research, development and commercialisation of ZW209, a T cell engager targeting DLL3.  Under the agreement, Zymeworks is eligible to receive an upfront payment of $55 million, a $40 million payment upon initiation of the Phase Ib… Read More

#Business & Investment #News

T cell engagers
#Cell Science #Drug discovery #T cell engagers #Whitepaper

Whitepaper – T-cell engagers: From drug discovery hurdles to next-gen solutions

Read this new Whitepaper from WuXi Biologics. Innovative platforms across key stages of TCE drug discovery, with real-world case studies on high-purity production and fit-for-purpose in vitro & in vivo studies. Proven approaches to navigate key development challenges, such as structural complexity, CRS risks, and tumour heterogeneity. Forward-looking strategies combining… Read More

#News

T cells
#Collaboration #Evotec #Oncology #Plectonic Biotech #T cell engagers

Partners explore T cell engaging approaches for solid tumours

Evotec and Plectonic Biotech have announced a research collaboration to explore a novel immunotherapy approach for solid tumours.   The collaboration aims to address key challenges that have so far limited the successful application of traditional T cell engager therapies in solid tumours by combining Plectonic’s programmable LOGIBODY technology with Evotec’s… Read More

#Business & Investment #Cancer Research #News

Immunotherapy
#AI #Drug discovery #Immunotherapy #Multi-omics #T cell engagers

How tech and collaboration are accelerating the development of T-cell engagers

Alistair Henry, Executive Vice President Chief Scientific Officer at UCB, explains that various factors that are helping drive the development of T-cell engagers (TCEs).  Why is immunotherapy discovery constantly evolving?   As scientists, we are trained to measure, analyse and interpret. We quantify binding affinities, map pathways, and build increasingly sophisticated models of disease. Read More

#Exclusive Content

#CellCentric #Fundraising #Oncology #T cell engagers

CellCentric raises $220m to advance trials of oral myeloma drug

CellCentric has completed an oversubscribed $220 million Series D financing led by Venrock Healthcare Capital Partners, with participation from new and existing investors.  The proceeds will support clinical trials for multiple myeloma therapy inobrodib. These will include continued enrolment of the company’s Phase II DOMMINO-1 study and initiation of the… Read More

#Business & Investment #News #Trending News

#Biotech #Investment #T cell engagers

Cytospire raises £61m to advance T cell engager pipeline 

UK biotech company Cytospire Therapeutics has closed a £61 million ($83 million) Series A financing round to advance T cell engagers, 4BIO Capital has announced.  The venture capital firm led the financing round, with proceeds allowing Cytospire to advance its pipeline of first-in-class pan-gamma delta T cell engagers. The company’s lead programme, CYT X300, is… Read More

#Business & Investment #News

T cells
#AI #Automation / robotics #Oncology #T cell engagers

How AI and robotics designed new cancer therapies

The latest episode of the DDW ‘In Conversation With’ series is available to listen to below. This week, Bruno Quinney speaks to Angus Sinclair, Chief Scientific Officer at LabGenius Therapeutics. LabGenius is a biotech using AI and robotics to design new cancer therapies, and in vivo efficacy data reveals… Read More

#Featured Podcasts #Podcasts

T cells
#Autoimmune disease #Gilead Sciences #Mergers and acquisitions #T cell engagers

Gilead to advance first T cell engager for autoimmune diseases

Gilead Sciences has entered an agreement to acquire Ouro Medicines, a biotechnology company focused on developing T cell engager therapies for autoimmune diseases.  The acquisition adds OM336 (gamgertamig), a clinical‑stage BCMAxCD3 T cell engager, to Gilead’s inflammation portfolio.   OM336 is designed to enable rapid and deep B cell depletion following… Read More

#Business & Investment #News

T cells
#Adagene #Collaboration #Colorectal cancer #Oncology #T cell engagers #Third Arc Bio

Adagene and Third Arc Bio collaborate on masked CD3 T cell engagers

Under a new agreement, Third Arc Bio will utilise Adagene’s SAFEbody technology platform to generate masked CD3 T cell engagers against unique tumour associated antigens.   In return, Third Arc Bio will receive rights to research, develop and commercialise two candidate molecules worldwide.   Adagene will receive an upfront payment of $5… Read More

#Business & Investment #News

#AACR #Clasp Therapeutics #Oncology #Phase I trial #T cell engagers

First precision T-cell engager for solid tumours enters the clinic

Clasp Therapeutics has announced the dosing of the initial patient in the GUARDIAN-101 Phase I trial of CLSP-1025, the first tumour-specific TCE to enter clinical development.   The company also presented non-clinical data for CLSP-1025 at the 2025 American Association for Cancer Research (AACR) Annual Meeting. … Read More

#Cancer Research #Editor's Choice #News

#Antibiotics #Autoimmune disease #Genetics / genomics #Oncology #Painkillers #T cell engagers

New DDW Highlights podcast: 25 November 2024

The latest episode of the DDW Highlights podcast is now available to listen to and watch below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week’s most exciting news stories all represent innovative solutions to the… Read More

#News

#Antibiotics #Autoimmune disease #Genetics / genomics #Oncology #Painkillers #T cell engagers

This week in drug discovery (18-22 November) 

News round-up for 18-22 November by DDW Senior Digital Content Editor Diana Spencer. This week’s most exciting news stories all represent innovative solutions to the treatment of disease, proving that ‘thinking outside the box’ can by the key to success in drug discovery. The top stories:… Read More

#News

T cell therapy in lupus
#Autoimmune disease #Cell therapy #Cullinan Therapeutics #Lupus #Preclinical investigations #T cell engagers

Preclinical data supports T cell engager in autoimmune disease

Positive preclinical data for novel CD19xCD3 T cell engager CLN-978 have supported its potential as a new therapeutic option for autoimmune diseases. Cullinan Therapeutics presented the preclinical results and a study schema for a planned Phase Ib study in patients with moderate to severe systemic lupus… Read More

#News

T cell attacking cancer cell
#CDR-Life #Immunotherapy #Oncology #Solid tumours #T cell engagers

CDR-Life progresses pipeline of T cell engagers for solid tumours

CDR-Life has announced new developments to its programme of antibody-based T cell engagers (TCE) targeting intracellular tumour antigens MAGE-A4 and PRAME via the major histocompatibility complex. The first patient has been dosed with CDR404, a novel, bispecific and bivalent antibody fragment-based TCE targeting MAGE-A4. Read More

#Cancer Research #News